THERAPEUTIC CONCENTRATION OF INFLIXIMAB IN THE BLOOD SERUM OF CROHN’S DISEASE PATIENTS RECEIVING ANTICYTOKINE THERAPY
Abstract
The therapeutic effect of infliximab (INFL) in Crohn’s disease (CD) patients receiving anticytokine therapy depends on the concentration of the medication in the blood serum. When INFL concentration in the blood serum is high (more than 20 μg/ml) the clinical and endoscopic remission of CD is observed in the patients. Upon the second administration INFL is not accumulated in the organism. After the induction course of INFL the level of the medication in the blood serum increases (more than 45 μg/ml), further its serological concentration gradually decreases approaching the values below the minimum. The transplantation of mesenchymal stromal cells of the bone marrow contributed to the increase of INFL level in the blood serum and to the recovery of sensitivity to INFL.
About the Authors
V. E. Sagynbaeva
State funded medical institution “City clinical hospital № 15 named after O. M. Filatov” Department of healthcare of Moscow
Russian Federation
Russian Federation
L. B. Lazebnik
State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov”
Russian Federation
Russian Federation
E. V. Golovanova
State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov”
Russian Federation
Russian Federation
References
1. Насонов Е. Л. Фактор некроза опухоли -α новая мишень для противовоспалительной терапии ревматоидного артрита // РМЖ.-2000.-т.8.-№ 17.-с.718-722.
2. Насонов Е. Л. Моноклональные антитела к фактору некроза опухоли -α в ревматологии // РМЖ.-2003.-№ 7.-с.718-722.
3. Сагынбаева В. Э., Лазебник Л. Б., Князев О. В., Ефремов Л. И. Антитела к инфликсимабу и к антигенам HLA-I и II класса как свидетели иммунного ответа на биолгическую терапию воспалительных заболеваниях кишечника // Экспер. и клинич. гастроэнтер. 2011. № 12. -с. -49-53.
4. Keating G. M., Perry C. M. Infliximab: an updated review of its use in Crohns disease and rheumatoid arthritis, BioDroge.-2002/-16 (2).111-48.
5. Han P. D., Cohen R. D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohns disease. Gruds.-2004.-64(16): 1767-77.
6. Remicade approved for children with Crohns disease. FDA Comsun.-2006 Jul-Aug.-40(4).-6.
7. Халиф И. Л. Биологическая терапия болезнь Крона // Методическая рекомендация. Выпуск 1. -2011. - Стр. 20.
8. Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and of infliximab // Clin pharmacokinet 2007; 46: 645-60.
9. Fasanmade AA., Adedokun OJ., Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis // Int J Clin Pharmacol Ther 2010; 48: 297-308.
10. Fasanmade AA., Adedokun OJ., Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis // Eur J Clin Pharmacol 2009; 65: 1211-28
11. Pollono EN., Lopez-Olivo MA., Iopez JA, et al. A systematic review of the effect of TNF-alpha antagonist on lipid profiles in patients with rheumatoid arthritis// Clin Rheum Dis 2010; 69: 817-21
12. Xu Z., Seitz K., Fasanmade A., Ford J., Williamson P., Xu W., Davis H. M., Zhou H. Population pharmacokinetics of infliximab in patients with ankylosind spondylitis, J Clin Pharmacol.-2008. Jun; 48 (6): 681-95. Epub 2008 Apr 9.
13. Elliott M. J., Maini R. N., Feldmann M., Long -Fox A., Chariles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis, Lancet.-1994.-Oct 22.-344 (8930).-1125-7).
Review
For citations:
Sagynbaeva V.E., Lazebnik L.B., Golovanova E.V. THERAPEUTIC CONCENTRATION OF INFLIXIMAB IN THE BLOOD SERUM OF CROHN’S DISEASE PATIENTS RECEIVING ANTICYTOKINE THERAPY. Experimental and Clinical Gastroenterology. 2017;(5):24-28. (In Russ.)
Views:
402
Email this article 